Tag: OCRA Research

OCRA Funded Research Identifies Genes Associated with Increased Risk of Ovarian Cancer

(May 21, 2019) Earlier this month, Nature Genetics published a study, in part funded by OCRA, that found 34 genes were connected to women developing the earliest stages of ovarian cancer…

Read on

OCRA Funded Study Aims to Increase Efficacy of PARP Inhibitors

(March 20, 2019) The Ovarian Cancer Dream Team, funded in part by OCRA, recently completed a Phase 1b Trial, which combined a PARP inhibitor with an HRR (homologous recombination repair) pathway inhibitor, such as PI3K, in order to increase the…

Read on

OCRA-Funded Research Indicates that Stem-Like Cells May Be Key to Preventing Recurrence

(March 15, 2019) Cell Reports recently published a study about a drug that, given in combination with chemotherapy, could greatly increase survival rates of ovarian cancer patients…

Read on

OCRA Awards $5.25 Million in Scientific Research Grants for 2019

(January 10, 2019) We’re pleased to announce OCRA’s newest research grants of $5.25 million to 23 top scientists at 14 top medical centers…

Read on

OCRA Funded Research Delves Deeper into How PARPi Work

(December 21, 2018) This month, researchers in Boston published their findings on how PARP inhibitors (PARPi) cause a chain reaction of responses from the tumor and its environment…

Read on

OCRA Research Shows How Cancer Cells Negatively Impact the Communication between the Ovary and Fallopian Tube

(October 22, 2018) A team at the University of Illinois at Chicago, including OCRA grantee Matthew Dean, PhD, recently discovered the role that cancer cells have on their immediate environment. The research was funded in part by OCRA…

Read on

OCRA Funded Research Reveals Immune Suppression in Ovarian Cancer

(October 15, 2018) This month in Nature, researchers from Weill Cornell published a study that helps to explain why the body’s natural immune response struggles to fight back against ovarian cancer…

Read on

OCRFA Funded Research Identifies Biomarker Linked to HGSOC Treatment and Survival Outcomes

(September 21, 2018) In an international collaboration funded in part by OCRFA, published recently in Cell, researchers used proteomics, the large-scale study of proteins, to identify an important indicator for treatment and disease-free survival in…

Read on

OCRFA Funded Study Focuses on the Dissemination of Ovarian Cancer

(April 27, 2018) An OCRFA supported study, recently published in Oncogene, delved into the mechanics of how ovarian cancer spreads throughout the body…

Read on

OCRFA Funded Study Explores Implant that Detects Ovarian Cancer Biomarker

(April 24, 2018) Science Advances recently published a study that succeeded in detecting HE4, a biomarker for high-grade serous ovarian cancer (HGSC), by implanting an optical sensor near a disease site in mice…

Read on

OCRFA Awards $5.3 Million in Scientific Research Grants for 2018

(January 25, 2018) OCRFA has just awarded more than $5.3 million in new scientific research grants for ovarian cancer, bringing our total investment in life-saving research to over $80 million…

Read on

OCRFA Research Shows Novel Combination Therapy Effective in Ovarian Cancer

(December 20, 2017) Cell Reports published new research from the Wistar Institute, which looked at the potential benefits of a therapy that combines PARP inhibitors and BET inhibitors for ovarian cancer patients without BRCA mutations…

Read on